Cargando…

RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases

BACKGROUND: The current standard-of-care treatment for brain metastases (BM)≥20 is Whole Brain Radiotherapy (WBRT), which can cause neurocognitive decline detrimental to patients’ quality of life, especially if their functional status is good on presentation. The benefits of Gamma Knife Surgery (GKS...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiani Liu, Sherry, Karlsson, Bengt, Tan, Choo Heng, Balamurugan, Vellayappan, Ang, Yvonne, Nga, Vincent, Yeo, Tseng Tsai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351275/
http://dx.doi.org/10.1093/noajnl/vdab071.091
_version_ 1783735939925803008
author Jiani Liu, Sherry
Karlsson, Bengt
Tan, Choo Heng
Balamurugan, Vellayappan
Ang, Yvonne
Nga, Vincent
Yeo, Tseng Tsai
author_facet Jiani Liu, Sherry
Karlsson, Bengt
Tan, Choo Heng
Balamurugan, Vellayappan
Ang, Yvonne
Nga, Vincent
Yeo, Tseng Tsai
author_sort Jiani Liu, Sherry
collection PubMed
description BACKGROUND: The current standard-of-care treatment for brain metastases (BM)≥20 is Whole Brain Radiotherapy (WBRT), which can cause neurocognitive decline detrimental to patients’ quality of life, especially if their functional status is good on presentation. The benefits of Gamma Knife Surgery (GKS) have been shown for BM≤10, but there is no consensus on the upper limit where GKS is no longer beneficial. We hypothesize that selected patients with ≥20 BM may benefit by replacing WBRT with GKS to preserve neurocognition without compromising intracerebral tumor control and overall survival, with additional treatments as needed. METHODOLOGY: This is retrospective analysis of 31 patients with ≥20 BM who underwent single-session GKS between 2016–2021. Twenty-two patients had ECOG of 0 at the time of GKS. Median number of BM at GKS was 30 (20–79) with median total tumour volume 4cm(3) (2–28 cm(3)). Median marginal dose was 20Gy (10-25Gy). RESULTS: Median overall survival following GKS was 14-months (95%CI 4-24months), justifying GKS in this population. 11/12 patients that died succumbed due to extracranial disease, while 1 patient, who was treated with WBRT before GKS, succumbed to intracranial tumor progression. Local tumor control achieved was achieved for 63% of patients at 2-years and distal tumor control in 24% of patients at 1.5-years without additional radiation treatment. Salvage GKS was given in seven patients and salvage WBRT in three. One local recurrence was surgically resected. Systemic treatment given to most patients probably contributed to intracranial tumor control. No patients developed significant neurocognitive deficits attributable to GKS during the follow-up period of median 7-months (Q1-Q3: 3-12months). CONCLUSION: Most patients treated with GKS for ≥20 BM have sufficient survival time to benefit from the treatment. Local and distal recurrences can be managed with systemic treatment, salvage GKS, or WBRT, resulting in intracerebral tumor control in vast majority of cases.
format Online
Article
Text
id pubmed-8351275
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83512752021-08-09 RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases Jiani Liu, Sherry Karlsson, Bengt Tan, Choo Heng Balamurugan, Vellayappan Ang, Yvonne Nga, Vincent Yeo, Tseng Tsai Neurooncol Adv Supplement Abstracts BACKGROUND: The current standard-of-care treatment for brain metastases (BM)≥20 is Whole Brain Radiotherapy (WBRT), which can cause neurocognitive decline detrimental to patients’ quality of life, especially if their functional status is good on presentation. The benefits of Gamma Knife Surgery (GKS) have been shown for BM≤10, but there is no consensus on the upper limit where GKS is no longer beneficial. We hypothesize that selected patients with ≥20 BM may benefit by replacing WBRT with GKS to preserve neurocognition without compromising intracerebral tumor control and overall survival, with additional treatments as needed. METHODOLOGY: This is retrospective analysis of 31 patients with ≥20 BM who underwent single-session GKS between 2016–2021. Twenty-two patients had ECOG of 0 at the time of GKS. Median number of BM at GKS was 30 (20–79) with median total tumour volume 4cm(3) (2–28 cm(3)). Median marginal dose was 20Gy (10-25Gy). RESULTS: Median overall survival following GKS was 14-months (95%CI 4-24months), justifying GKS in this population. 11/12 patients that died succumbed due to extracranial disease, while 1 patient, who was treated with WBRT before GKS, succumbed to intracranial tumor progression. Local tumor control achieved was achieved for 63% of patients at 2-years and distal tumor control in 24% of patients at 1.5-years without additional radiation treatment. Salvage GKS was given in seven patients and salvage WBRT in three. One local recurrence was surgically resected. Systemic treatment given to most patients probably contributed to intracranial tumor control. No patients developed significant neurocognitive deficits attributable to GKS during the follow-up period of median 7-months (Q1-Q3: 3-12months). CONCLUSION: Most patients treated with GKS for ≥20 BM have sufficient survival time to benefit from the treatment. Local and distal recurrences can be managed with systemic treatment, salvage GKS, or WBRT, resulting in intracerebral tumor control in vast majority of cases. Oxford University Press 2021-08-09 /pmc/articles/PMC8351275/ http://dx.doi.org/10.1093/noajnl/vdab071.091 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Jiani Liu, Sherry
Karlsson, Bengt
Tan, Choo Heng
Balamurugan, Vellayappan
Ang, Yvonne
Nga, Vincent
Yeo, Tseng Tsai
RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title_full RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title_fullStr RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title_full_unstemmed RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title_short RADI-21. Feasibility of Gamma Knife Surgery for patients with 20 or more brain metastases
title_sort radi-21. feasibility of gamma knife surgery for patients with 20 or more brain metastases
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351275/
http://dx.doi.org/10.1093/noajnl/vdab071.091
work_keys_str_mv AT jianiliusherry radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT karlssonbengt radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT tanchooheng radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT balamuruganvellayappan radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT angyvonne radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT ngavincent radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases
AT yeotsengtsai radi21feasibilityofgammaknifesurgeryforpatientswith20ormorebrainmetastases